◀ Back to MYC
MYC — RBL1
Pathways - manually collected, often from reviews:
-
FastForward regulation:
RBL1
→
MYC
(transcriptional regulation, increase)
Chen et al., Cell 2002
Evidence: REG, PROMACTIVITY, DNABINDING
-
KEGG Cell cycle:
Complex of E2F4-E2F5-RBL1-RBL2-TFDP1-TFDP2
→
MYC
(gene expression, repression)
-
KEGG TGF-beta signaling pathway:
Complex of E2F4-E2F5-RBL1-RBL2-TFDP1
→
MYC
(gene expression, repression)
-
NCI Pathway Database Validated targets of C-MYC transcriptional repression:
p107 (RBL1)
→
MYC/Max complex (MYC-MAX)
(transcription, inhibits)
Luo et al., Oncogene 2004*, Penn et al., EMBO J 1990*, Facchini et al., Mol Cell Biol 1997*
Evidence: mutant phenotype, reporter gene, physical interaction
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Hoang et al., Mol Cell Biol 1995
(Burkitt Lymphoma...) :
A link between increased transforming activity of lymphoma derived
MYC mutant alleles, their defective
regulation by
p107 , and altered phosphorylation of the c-Myc transactivation domain
Beijersbergen et al., EMBO J 1994
:
Our data suggest that
p107 can
control c-Myc activity through direct binding to the transactivation domain and that c-Myc is a target for p107 mediated growth suppression